Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance (SPACEWALK)
ALCMI-011: Study of Plasma Next Generation Sequencing for Assessment, Characterization, Evaluation of Patients With ALK Resistance (SPACEWALK)
Sponsor: Addario Lung Cancer Medical Institute
This observational or N/A phase trial investigates Non-Small Cell Lung Cancer and is currently completed. Addario Lung Cancer Medical Institute leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Feb 2025 — Nov 2025 [monthly]
Completed
-
Sep 2024 — Feb 2025 [monthly]
Completed
-
Aug 2024 — Sep 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting
▶ Show 9 earlier versions
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
Feb 2023 — Mar 2024 [monthly]
Active Not Recruiting
-
Feb 2022 — Feb 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Mar 2019 — Oct 2020 [monthly]
Recruiting
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Addario Lung Cancer Medical Institute
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .